{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:17:13Z","timestamp":1767665833698},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Studies performed in animal models of corneal neovascularization suggested the possible efficacy of a treatment with propranolol. Corneal neovascularization is one of the most feared complications of Stevens\u2013Johnson syndrome that frequently involves ocular surface. We report the first 2 patients with severe ocular neo-vascularization treated with different degrees of success, with propranolol eye drops.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>Two patients with corneal neovascularization complicating the Stevens\u2013Johnson syndrome, not responsive to steroids and cyclosporine, were treated with propranolol eye drops.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Corneal neovascularization was detected by ophthalmoscopic evaluation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Topical treatment with propranolol eye drops at different concentrations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Both patients reported dramatic subjective benefits (reduction of photophobia and discomfort) without adverse effects, and in the patient with a less advanced disease, an objective reduction of neovascularization and an improved visual acuity was observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This experience suggests that propranolol might be an inexpensive, safe and effective treatment in counteracting the progression of corneal neovascularization.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013002","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T21:26:40Z","timestamp":1541539600000},"page":"e13002","source":"Crossref","is-referenced-by-count":5,"title":["Propranolol eye drops in patients with corneal neovascularization"],"prefix":"10.1097","volume":"97","author":[{"given":"Luca","family":"Filippi","sequence":"first","affiliation":[{"name":"Neonatal Intensive Care Unit, Medical Surgical Fetal-Neonatal Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"de Libero","sequence":"additional","affiliation":[{"name":"Pediatric Ophthalmology Unit, \u201cA. Meyer\u201d University Children's Hospital, Florence"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Zamma Gallarati","sequence":"additional","affiliation":[{"name":"Pediatric Ophthalmology Unit, \u201cA. Meyer\u201d University Children's Hospital, Florence"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pina","family":"Fortunato","sequence":"additional","affiliation":[{"name":"Pediatric Ophthalmology Unit, \u201cA. Meyer\u201d University Children's Hospital, Florence"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Piozzi","sequence":"additional","affiliation":[{"name":"Pediatric Ophthalmology Unit, Niguarda Ca\u2019 Granda Metropolitan Hospital, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1097\/ICO.0000000000000646","article-title":"Incidence of Stevens\u2013Johnson syndrome and chemical burns to the eye","volume":"34","author":"White","year":"2015","journal-title":"Cornea"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R3-20230915","first-page":"157","article-title":"Risk factors for the development of ocular complications of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"145","author":"Gueudry","year":"2009","journal-title":"Arch Dermatol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000070938","article-title":"Dermatological and ophthalmological sequels in toxic epidermal necrolysis","volume":"207","author":"Magina","year":"2003","journal-title":"Dermatology"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jtos.2016.02.001","article-title":"Acute and chronic ophthalmic involvement in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis\u2014a comprehensive review and guide to therapy. II. Ophthalmic disease","volume":"14","author":"Kohanim","year":"2016","journal-title":"Ocul Surf"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/ICU.0000000000000312","article-title":"Ocular manifestations of Stevens\u2013Johnson syndrome and their management","volume":"27","author":"Saeed","year":"2016","journal-title":"Curr Opin Ophthalmol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/08820538.2011.588652","article-title":"Inflammatory corneal neovascularization: etiopathogenesis","volume":"26","author":"Clements","year":"2011","journal-title":"Semin Ophthalmol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3109\/08820538.2015.1114841","article-title":"Chronic ocular complications of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: the role of systemic immunomodulatory therapy","volume":"31","author":"Chang","year":"2016","journal-title":"Semin Ophthalmol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/jop.2012.0009","article-title":"Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye","volume":"29","author":"Prabhasawat","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaapos.2011.12.153","article-title":"Bilateral response after unilateral subconjunctival bevacizumab injection in a child with Stevens\u2013Johnson syndrome","volume":"16","author":"Kesarwani","year":"2012","journal-title":"J AAPOS"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ophtha.2015.10.027","article-title":"Adjuvant role of amniotic membrane transplantation in acute ocular Stevens\u2013Johnson syndrome: a randomized control trial","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"N Engl J Med"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2133.2010.09848.x","article-title":"Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action","volume":"163","author":"Storch","year":"2010","journal-title":"Br J Dermatol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/pde.12192","article-title":"Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy","volume":"30","author":"Chen","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/med.21336","article-title":"Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the \u03b2-adrenergic system","volume":"35","author":"Filippi","year":"2015","journal-title":"Med Res Rev"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1167\/iovs.10-5536","article-title":"Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade","volume":"52","author":"Ristori","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaophthalmol.2013.1476","article-title":"Attenuation of choroidal neovascularization by \u03b2(2)-adrenoreceptor antagonism","volume":"131","author":"Lavine","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"8228","DOI":"10.1167\/iovs.15-17169","article-title":"Ocular safety of intravitreal propranolol and its efficacy in attenuation of choroidal neovascularization","volume":"56","author":"Nourinia","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"1570.e6","DOI":"10.1016\/j.jpeds.2013.07.049","article-title":"Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives","volume":"163","author":"Filippi","year":"2013","journal-title":"J Pediatr"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1515\/jpm-2015-0357","article-title":"Oral propranolol in early stages of retinopathy of prematurity","volume":"44","author":"Bancalari","year":"2016","journal-title":"J Perinat Med"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/jop.2013.0238","article-title":"The effect of ( receptor blockade through propranolol on corneal neovascularization","volume":"30","author":"Simavli","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"key":"R22-20230915","first-page":"39","article-title":"Topical timolol inhibits corneal neovascularization in rabbits","volume":"6","author":"Kasiri","year":"2017","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"R23-20230915","first-page":"S32","article-title":"Comparison of topically administered bevacizumab and propranolol in treatment of corneal neovascularization in rabbits","volume":"4","author":"Kasiri","year":"2017","journal-title":"Indo Am J P Sci"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/jop.2017.0119","article-title":"The Effect of 0.5% timolol maleate on corneal (lymph) angiogenesis in a murine suture model","volume":"34","author":"Cho","year":"2018","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201811090-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:10:11Z","timestamp":1694812211000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201811090-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":24,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013002","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}